- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- Facing pharmacy trends for the remainder of the year
- Rite Aid posts third consecutive quarterly profit as company expands Wellness+
- Senate passes Drug Quality and Security Act
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
MONTREAL — Valeant Pharmaceuticals International has acquired rights to a drug used to treat a symptom of age-related macular degeneration, the drug maker said.
Valeant announced that it acquired the injected drug Visudyne (verteporfin) from QLT, a company based in Vancouver, Canada.
Valeant said it paid $62.5 million upfront for all U.S. rights and available inventories for the drug, which had U.S. sales of about $21 million in 2011, and another $50 million upfront for rights to non-U.S. sales, which were about $14 million.